Representation of Native Hawaiian and Pacific Islander Individuals in Clinical Trials.

ABSTRACT:

Importance

Having diverse participants in clinical trials ensures new drug products work well across different demographic groups, making health care safer and more effective for everyone. Information on the extent of Native Hawaiian and Pacific Islander participation in clinical trials is limited.

Objective

To examine representation of Native Hawaiian and Pacific Islanders in clinical trials leading to the first US Food and Drug Administration (FDA) approvals for the 10 drug products with the top worldwide sales forecasts in 2024.

Design, setting, and participants

Cross-sectional secondary analysis of existing data from clinical trials that took place from 2006 to 2021 in the US. All clinical trials that were included in the FDA first approval application for the 10

SUBMITTER: Taira DA 

PROVIDER: S-EPMC11522938 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature